| Literature DB >> 34113136 |
Teng Zhou1,2, Mengjiao Kuang1, Shirui Huang1, Jizhen Li1, Qipeng Xie1.
Abstract
OBJECTIVE: Central nervous system infections (CNSI) are serious diseases that endanger human health. Identifying pathogens and their susceptibility to antibiotics, and promptly using antibiotics under this guidance is essential for treatment. The purpose of this study is to investigate the pathogen characteristics of CNSI patients, which can help clinicians choose appropriate empiric antibiotic .Entities:
Keywords: bacterial culture; cerebrospinal fluid; drug resistance; epidemiological characteristics
Year: 2021 PMID: 34113136 PMCID: PMC8184139 DOI: 10.2147/IDR.S312175
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Positive Profile of Cerebrospinal Fluid Culture Results
| Character | rouping | Cases (n) | Ratio (%) |
|---|---|---|---|
| Gender | Male | 94 | 56.0 |
| Female | 74 | 44.0 | |
| Age | Newborn (≤28 days) | 46 | 27.4 |
| ≤12 years old | 68 | 40.5 | |
| > 12 years old | 54 | 32.1 | |
| Season | Spring (March-May) | 52 | 31.0 |
| Summer (June-August) | 42 | 25.0 | |
| Autumn (September-November) | 35 | 20.8 | |
| Winter (December-February) | 39 | 23.2 |
Figure 1Time distribution diagram of culture positive result.
Figure 2Composite pie chart of clinical symptoms of patients with positive cerebrospinal fluid culture.
Detection of Cerebrospinal Fluid Pathogen in Different Sex, Age and Season
| Pathogen Name | Number of Strains (n=168) | Gender | Age (Years Old) | Season | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male (n=94) | Female (n=74) | Chi-Square Value | P value | Newborns (n=46) | ≤12 (n=68) | >12 (n=54) | Chi-Square Value | P value | Spring (n=52) | Summer (n=42) | Autumn (n=35) | Winter (n=39) | Chi-Square Value | P value | ||
| G- bacteria | 61 (36.3) | 34 (36.2) | 27 (36.5) | 0.002 | 0.966 | 16 (34.8) | 19 (27.9) | 26 (48.1) | 5.378 | 0.068 | 19 (36.5) | 15 (35.7) | 16 (45.7) | 11 (28.2) | 2.454 | 0.484 |
| Escherichia coli | 23 (13.7) | 13 (13.8) | 10 (13.5) | 0.004 | 0.953 | 12 (26.1) | 10 (14.7) | 1 (1.9) | 12.447 | 0.002 | 10 (19.2) | 6 (14.3) | 3 (8.6) | 4 (10.3) | 2.529 | 0.470 |
| Klebsiella pneumoniae | 10 (6.0) | 6 (6.4) | 4 (5.4) | 0.090 | 0.764 | 2 (4.3) | 2 (2.9) | 6 (11.1) | 3.421 | 0.183 | 1 (1.9) | 1 (2.4) | 6 (17.1) | 2 (5.1) | 7.882 | 0.026 |
| Acinetobacter baumannii | 7(4.2) | 4 (4.3) | 3 (4.1) | 0.004 | 1.000 | 0 | 1 (1.5) | 6 (11.1) | 7.711 | 0.008 | 3 (5.8) | 2 (4.8) | 0 | 2 (5.1) | 2.057 | 0.591 |
| Enterobacter cloacae | 5 (3.0) | 2 (2.1) | 3 (4.1) | 0.532 | 0.655 | 1 (2.2) | 3 (4.4) | 1 (1.9) | 0.766 | 0.736 | 2 (3.8) | 3 (7.1) | 0 | 0 | 3.805 | 0.198 |
| Enterobacter aerogenes | 2 (1.2) | 2 (2.1) | 0 | – | – | 0 | 0 | 2 (3.7) | - | - | 0 | 0 | 2 (5.7) | 0 | - | - |
| Agaricus pseudomonas | 2 (1.2) | 0 | 2 (2.7) | – | – | 0 | 0 | 2 (3.7) | – | – | 2 (3.8) | 0 | 0 | 0 | – | – |
| Pseudomonas aeruginosa | 2 (1.2) | 1 (1.1) | 1 (1.4) | – | – | 0 | 0 | 2 (3.7) | – | – | 0 | 1 (2.4) | 1 (2.9) | 0 | – | – |
| Salmonella Group B | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 1 (1.5) | 0 | – | – | 0 | 0 | 1 (2.9) | 0 | – | – |
| Klebsiella oxytoca | 1 (0.6) | 0 | 1 (1.4) | – | – | 0 | 0 | 1 (1.9) | – | – | 1 (1.9) | 0 | 0 | 0 | – | – |
| Golden Bacillus producing indole | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 0 | 1 (1.9) | – | – | 0 | 0 | 1 (2.9) | 0 | – | – |
| Pseudomonas flavescens | 1 (0.6) | 0 | 1 (1.4) | – | – | 0 | 1 (1.5) | 0 | – | – | 0 | 0 | 1 (2.9) | 0 | – | – |
| Moraxella catarrhalis | 1 (0.6) | 0 | 1 (1.4) | – | – | 0 | 0 | 1 (1.9) | – | – | 0 | 1 (2.4) | 0 | 0 | – | – |
| Flavobacterium septicum meningitidis | 1 (0.6) | 0 | 1 (1.4) | – | – | 1 (2.2) | 0 | 0 | – | – | 0 | 1 (2.4) | 0 | 0 | – | – |
| Neisseria meningitidis | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 1(1.5) | 0 | – | – | 0 | 0 | 0 | 1 (2.6) | – | – |
| Proteus mirabilis | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 0 | 1 (1.9) | – | – | 0 | 0 | 1 (2.9) | 0 | – | – |
| Burkholderia cepacia | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 0 | 1 (1.9) | – | – | 0 | 0 | 0 | 1 (2.6) | – | – |
| Serratia marcescens | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 0 | 1 (1.9) | – | – | 0 | 0 | 0 | 1 (2.6) | – | – |
| G+ bacteria | 100 (59.5) | 58 (61.7) | 42 (56.8) | 0.420 | 0.517 | 30 (65.2) | 47 (69.1) | 23 (42.6) | 9.642 | 0.008 | 31 (59.6) | 25 (59.5) | 19 (54.3) | 25 (64.1) | 0.738 | 0.864 |
| Streptococcus agalactiae | 32 (19.0) | 11 (11.7) | 21 (28.4) | 7.468 | 0.006 | 24 (52.2) | 8 (11.8) | 0 | 47.782 | <0.001 | 13 (25.0) | 8 (19.0) | 3 (8.6) | 8 (20.5) | 3.740 | 0.291 |
| Streptococcus pneumoniae | 23 (13.7) | 16 (17.0) | 7 (9.5) | 2.004 | 0.157 | 0 | 21 (30.9) | 2 (3.7) | 28.863 | <0.001 | 6 (11.5) | 2 (4.8) | 7 (20.0) | 8 (20.5) | 5.753 | 0.124 |
| Staphylococcus epidermidis | 22 (13.1) | 16 (17.0) | 6 (8.1) | 2.890 | 0.089 | 3 (6.5) | 9 (13.2) | 10 (18.5) | 3.143 | 0.208 | 3 (5.8) | 11 (26.2) | 3 (8.6) | 5 (12.8) | 9.413 | 0.024 |
| Staphylococcus aureus | 6 (3.6) | 5 (5.3) | 1 (1.4) | 1.893 | 0.230 | 2 (4.3) | 1 (1.5) | 3 (5.6) | 1.736 | 0.440 | 1 (1.9) | 2 (4.8) | 2 (5.7) | 1 (2.6) | 1.434 | 0.764 |
| Enterococcus faecalis | 3 (1.8) | 2 (2.1) | 1 (1.4) | – | – | 0 | 2 (2.9) | 1 (1.9) | – | – | 1 (1.9) | 1 (2.4) | 0 | 1 (2.6) | – | – |
| Staphylococcus hominis | 2 (1.2) | 1 (1.1) | 1 (1.4) | – | – | 0 | 1 (1.5) | 1 (1.9) | – | – | 0 | 0 | 1 (2.9) | 1 (2.6) | – | – |
| Staphylococci cephalus | 2 (1.2) | 1 (1.1) | 1 (1.4) | – | – | 0 | 0 | 2 (3.7) | – | – | 2 (3.8) | 0 | 0 | 0 | – | – |
| Enterococcus gallinarum | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 0 | 1 (1.9) | – | – | 0 | 1 (2.4) | 0 | 0 | – | – |
| Staphylococci coli | 1 (0.6) | 0 | 1 (1.4) | – | – | 0 | 1 (1.5) | 0 | – | – | 1 (1.9) | 0 | 0 | 0 | – | – |
| Enterococcus urethrae | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 0 | 1 (1.9) | – | – | 1 (1.9) | 0 | 0 | 0 | – | – |
| Streptococcus bovis | 1 (0.6) | 1 (1.1) | 0 | – | – | 1 (2.2) | 0 | 0 | – | – | 0 | 0 | 0 | 1 (2.6) | – | – |
| Streptococcus granulosus | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 1 (1.5) | 0 | – | – | 1 (1.9) | 0 | 0 | 0 | – | – |
| Staphylococcus haemolyticus | 1 (0.6) | 0 | 1 (1.4) | – | – | 0 | 1 (1.5) | 0 | – | – | 0 | 0 | 1 (2.9) | 0 | – | – |
| Staphylococcus squirrels | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 0 | 1 (1.9) | – | – | 0 | 0 | 1 (2.9) | 0 | – | – |
| Staphylococcus aureus Ureaplasma urealyticum subsp. | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 1 (1.5) | 0 | – | – | 1 (1.9) | 0 | 0 | 0 | – | – |
| Staphylococcus cephalus subspecies cephalus | 1 (0.6) | 0 | 1 (1.4) | – | – | 0 | 0 | 1 (1.9) | – | – | 1 (1.9) | 0 | 0 | 0 | – | – |
| Pediococcus pentosaceus | 1 (0.6)1 | 0 | 1 (1.4) | – | – | 0 | 1 (1.5) | 0 | – | – | 0 | 0 | 1 (2.9) | 0 | – | – |
| Fungus | 7 (4.2) | 2 (2.1) | 5 (6.8) | 2.222 | 0.136 | 0 | 2 (2.9) | 5 (9.3) | 4.888 | 0.069 | 2 (3.8) | 2 (4.8) | 0 | 3 (7.7) | 2.660 | 0.463 |
| Cryptococcus neoformans | 6 (3.6) | 1 (1.1) | 5 (6.8) | 3.896 | 0.088 | 0 | 1 (1.5) | 5 (9.3) | 3.905 | 0.087 | 1 (1.9) | 2 (4.8) | 0 | 3 (7.7) | 1.789 | 0.378 |
| Candida albicans | 1 (0.6) | 1 (1.1) | 0 | – | – | 0 | 1 (1.5) | 0 | – | – | 1 (1.9) | 0 | 0 | 0 | – | – |
Summary of Gram-Positive Antibacterial Activity in vitro
| Antibacterial Drug Name | Streptococcus mastitidis (n=32) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| S | R/I | M | S | R/I | M | S | R/I | M | |
| Ampicillin | 46.9 | 0 | 53.1 | – | – | – | 45.5 | 0 | 54.5 |
| Ertapenem | – | – | – | 69.6 | 0 | 30.4 | – | – | – |
| Compound sulfamethoxazole | – | – | – | 30.4 | 69.5 | 0 | 36.4 | 63.6 | 0 |
| Erythromycin | 6.3 | 15.6 | 78.1 | 4.3 | 95.7 | 0 | 45.5 | 54.5 | 0 |
| Ciprofloxacin | – | – | – | – | – | – | 63.6 | 36.4 | 0 |
| Rifampin | – | – | – | – | – | – | 86.4 | 13.6 | 0 |
| Linezolid | 96.9 | 0 | 3.1 | 69.6 | 0 | 30.4 | – | – | – |
| Clindamycin hydrochloride | 6.3 | 40.6 | 53.1 | – | – | – | 90.9 | 9.1 | 0 |
| Chloromycetin | – | – | – | 82.6 | 13.0 | 4.3 | – | – | – |
| Meropenem | – | – | – | 39.1 | 47.8 | 13.0 | – | – | – |
| Moxifloxacin | 40.6 | 3.1 | 56.3 | 73.9 | 0 | 26.1 | – | – | – |
| Gentamicin | – | – | – | – | – | – | 77.3 | 22.7 | 0 |
| Tetracycline | 3.1 | 46.9 | 50.0 | 17.4 | 82.6 | 0 | – | – | – |
| Tigecycline | 37.5 | 0 | 62.5 | – | – | – | 50.0 | 0 | 50.0 |
| Penicillin | – | – | – | 21.7 | 65.2 | 13.0 | 9.1 | 63.6 | 27.3 |
| Penicillin other | – | – | – | 26.1 | 0 | 73.9 | – | – | – |
| Ceftriaxone | – | – | – | 34.8 | 52.2 | 13.0 | – | – | – |
| Ceftriaxone other | – | – | – | 60.9 | 13.0 | 26.1 | – | – | – |
| Cefotaxime | – | – | – | 39.1 | 56.5 | 4.3 | – | – | – |
| Cefotaxime other | – | – | – | 56.5 | 17.4 | 26.1 | – | – | – |
| Vancomycin | 96.9 | 0 | 3.1 | 95.7 | 4.3 | 0 | – | – | – |
| Ofloxacin | – | – | – | 65.2 | 0 | 34.8 | – | – | – |
| Levofloxacin | 75.0 | 25.0 | 0 | – | – | – | 63.6 | 36.4 | 0 |
| Amoxicillin | – | – | – | 69.6 | 8.6 | 21.7 | – | – | – |
| Telithromycin | – | – | – | 73.9 | 0 | 26.1 | – | – | – |
| Oxacillin | – | – | – | – | – | – | 18.2 | 81.8 | 0 |
| Clindamycin | – | – | – | – | – | – | 68.2 | 0 | 31.8 |
Notes: To ensure the reliability of experimental results, we only performed resistance analysis on bacteria with the number of bacterial strains exceeding 10. S: Sensitivity; I: Intermediate; R: Resistance; M: Missing.
Summary of Gram-Negative Antibacterial Activity in vitro
| Antibacterial Drug Name | ||||||
|---|---|---|---|---|---|---|
| S | R/I | M | S | R/I | M | |
| Amoxicillin/clavulanic acid | 47.8 | 4.3 | 47.8 | – | – | – |
| Ampicillin | 17.4 | 82.6 | 0 | 0 | 50.0 | 50.0 |
| Ertapenem | 39.1 | 0 | 60.9 | 30.0 | 0 | 70.0 |
| Compound sulfamethoxazole | 26.1 | 69.6 | 4.3 | 80.0 | 20.0 | 0 |
| Meropenem | 47.8 | 4.3 | 47.8 | 40.0 | 10.0 | 50.0 |
| Gentamicin | 65.2 | 34.8 | 0 | 70.0 | 30.0 | 0 |
| Ceftriaxone | 43.5 | 52.2 | 4.3 | 50.0 | 50.0 | 0 |
| Levofloxacin | 34.8 | 60.9 | 4.3 | 80.0 | 20.0 | 0 |
| Ampicillin/sulbactam | 17.4 | 30.4 | 52.2 | 40.0 | 40.0 | 20.0 |
| Aztreonam | 69.6 | 30.4 | 0 | 70.0 | 30.0 | 0 |
| Amikacin | 95.7 | 4.3 | 0 | 50.0 | 10.0 | 40.0 |
| Ceftazidime | 73.9 | 26.1 | 0 | 70.0 | 30.0 | 0 |
| Cefepime | 73.9 | 26.1 | 0 | 70.0 | 30.0 | 0 |
| Imipenem | 95.7 | 4.3 | 0 | 70.0 | 30.0 | 0 |
| Piperacillin/tazobactam | 95.7 | 0 | 4.3 | 70.0 | 30.0 | 0 |
| Cefotetan | 39.1 | 0 | 60.9 | 30.0 | 20.0 | 50.0 |
| Tobramycin | 60.9 | 30.4 | 8.7 | 70.0 | 10.0 | 20.0 |
Notes: To ensure the reliability of experimental results, we only performed resistance analysis on bacteria with the number of bacterial strains exceeding 10. S: Sensitivity; I: Intermediate; R: Resistance; M: Missing.
Summary of CSF Index of Positive Culture Results
| Indicator | Gram - Bacteria | Gram + Bacteria | Statistics | P value |
|---|---|---|---|---|
| White blood cell count (10*6) | 1120.00 (192.50, 4130.00) | 680.00 (144.00, 2700.00) | −1.254 | 0.210 |
| Red blood cell count (10*6) | 97.50 (10.00, 752.50) | 90.00 (9.00, 565.00) | −0.019 | 0.985 |
| Neutrophil ratio (%) | 85 (69, 93) | 80 (60, 91) | −1.567 | 0.117 |
| Lymphocyte ratio (%) | 14 (5, 30) | 18 (8, 39) | −1.677 | 0.094 |
| Glucose quantification (g/L) | 1.67±1.09 | 1.83±1.15 | −0.903 | 0.368 |
| Chloride (mmol/L) | 113.47±8.82 | 115.92±6.86 | −1.839 | 0.069 |
| Protein quantification (g/L) | 2.68 (0.96, 4.26) | 2.51 (1.05, 3.28) | −0.203 | 0.839 |
Association of G- and G+ Bacteria with CSF Indices in Children (≤12 Years)
| Indicator | Gram - Bacteria | Gram + Bacteria | Statistics | P value |
|---|---|---|---|---|
| White blood cell count (10*6) | 1040.00 (215.00, 3400.00) | 645.00 (152.25, 3150.00) | −0.633 | 0.527 |
| Red blood cell count (10*6) | 84 (68, 90) | 79 (60, 92) | −0.377 | 0.706 |
| Neutrophil ratio (%) | 18 (7, 30) | 18 (7, 37) | −0.626 | 0.531 |
| Lymphocyte ratio (%) | 1.43±0.97 | 1.70±1.09 | −1.234 | 0.013 |
| Glucose quantification (g/L) | 111.40±9.31 | 115.21±6.24 | −2.531 | 0.069 |
| Chloride (mmol/L) | 2.49 (1.03, 4.33) | 2.76 (1.00, 3.28) | −0.033 | 0.974 |
Association of G- and G+ Bacteria with CSF Indices in Adult (>12 Years)
| Indicator | Gram - Bacteria | Gram + Bacteria | Statistics | P value | |
|---|---|---|---|---|---|
| White blood cell count (10*6) | 1200 (185, 557) | 750 (101, 1835) | −1.279 | 0.201 | |
| Red blood cell count (10*6) | 89 (71, 96) | 82 (54, 88) | −1.841 | 0.066 | |
| Neutrophil ratio (%) | 10 (4, 27) | 18 (10, 52) | −1.749 | 0.080 | |
| Lymphocyte ratio (%) | 1.97±1.18 | 2.30±1.28 | −0.935 | 0.354 | |
| Glucose quantification (g/L) | 116.18±7.47 | 118.41±8.39 | −0.973 | 0.336 | |
| Chloride (mmol/L) | 2.74 (0.94, 3.16) | 1.74 (1.09, 3.12) | −0.549 | 0.583 | |